Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 40,985 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 40,985 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $3,769,800.30. Following the completion of the transaction, the chief executive officer owned 194,309 shares in the company, valued at $17,872,541.82. This trade represents a 17.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Christopher Peetz also recently made the following trade(s):

• On Monday, February 2nd, Christopher Peetz sold 9,108 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $103.30, for a total transaction of $940,856.40.
• On Monday, January 26th, Christopher Peetz sold 6,831 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $96.19, for a total transaction of $657,073.89.
• On Thursday, January 22nd, Christopher Peetz sold 7,098 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total value of $662,456.34.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock traded up $3.91 during mid-day trading on Tuesday, hitting $96.55. The company’s stock had a trading volume of 865,362 shares, compared to its average volume of 830,531. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.55 and a current ratio of 2.67. The company’s fifty day simple moving average is $95.73 and its 200-day simple moving average is $80.84. Mirum Pharmaceuticals, Inc. has a 52 week low of $36.88 and a 52 week high of $109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.13). The business had revenue of $148.93 million for the quarter, compared to analyst estimates of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The company’s revenue for the quarter was up 49.8% on a year-over-year basis. During the same period in the prior year, the business earned $1.00 EPS. On average, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Institutional Trading of Mirum Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Cullen Frost Bankers Inc. purchased a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at approximately $30,000. MCF Advisors LLC lifted its holdings in Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after acquiring an additional 185 shares during the period. Eurizon Capital SGR S.p.A. purchased a new position in Mirum Pharmaceuticals in the fourth quarter worth $32,000. CIBC Private Wealth Group LLC bought a new position in Mirum Pharmaceuticals in the 4th quarter valued at $32,000. Finally, Quantbot Technologies LP bought a new position in Mirum Pharmaceuticals in the 3rd quarter valued at $33,000.

Analysts Set New Price Targets

A number of brokerages recently commented on MIRM. Royal Bank Of Canada decreased their target price on Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating for the company in a research report on Thursday, February 26th. Raymond James Financial reissued a “strong-buy” rating and issued a $110.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $130.00 target price on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. Wall Street Zen cut Mirum Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 28th. Finally, HC Wainwright lifted their price target on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $117.00.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.